EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Why and how to treat Ph-like ALL?

Kathryn G Roberts

Best Practice & Research Clinical Haematology · 2018-12 · 31 (4) · 351-356

DOI: 10.1016/j.beha.2018.09.003 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Best Practice & Research Clinical Haematology, 2018-12. Verfasst von Kathryn G Roberts. Beteiligte Einrichtung: Department of Pathology, St Jude Children's Research Hospital, 262 Danny Thomas Place, MS342, Memphis, TN, 38105, USA. Electronic address: kathryn.ro…. Hauptthemen laut MEDLINE: Fusion Proteins, bcr-abl, Mutation, Philadelphia Chromosome, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL), or BCR-ABL1-like ALL, is a high-risk subtype of B-cell precursor ALL characterized by a gene expression profile similar to Ph-positive ALL, a high frequency of IKZF1 alterations, and poor outcome. The prevalence of Ph-like ALL is common among all ages, ranging from 10% to 15% in children to over 25% in young adults. Patients with Ph-like ALL harbor a diverse range of genetic alterations that activate cytokine receptor and kinase signaling and can be targeted with tyrosine kinase inhibitors. The majority of Ph-like ALL alterations are divided into two main groups based on activation of ABL-class or JAK-STAT alterations. Accordingly, preclinical studies and anecdotal reports suggest patients harboring ABL-class fusions are candidates for ABL1-inhibitors, whilst alterations activating the JAK-STAT pathway may be amenable to treatment with JAK inhibitors. Diagnostic screening approaches and precision medicine trials are now being developed and implemented to test the efficacy of targeted therapy with a backbone of chemotherapy, similar to the treatment of Ph-positive ALL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fusion Proteins, bcr-ablMutationPhiladelphia ChromosomePrecursor Cell Lymphoblastic Leukemia-LymphomaAdolescentAdultChildChild, PreschoolFemaleHumansInfantMaleProtein Kinase Inhibitors

Stichwörter der Autor:innen

ABLALLAcute lymphoblastic leukemiaBCR-ABL1-like ALLDasatinibJAK-STATLarotrectinibPh-like ALLPhiladelphia chromosome-like ALLRuxolitinibSt Jude TXVII

Substanzen

BCR-ABL1 fusion protein, humanProtein Kinase InhibitorsFusion Proteins, bcr-abl

Autor:innen und Institutionen

  • Department of Pathology, St Jude Children's Research Hospital, 262 Danny Thomas Place, MS342, Memphis, TN, 38105, USA. Electronic address: kathryn.roberts@stjude.org.

Zitieren

APA

Roberts, K. G. (2018). Why and how to treat Ph-like ALL?. Best Practice & Research Clinical Haematology, 31(4), 351-356. https://doi.org/10.1016/j.beha.2018.09.003

Vancouver

Roberts KG. Why and how to treat Ph-like ALL?. Best Practice & Research Clinical Haematology. 2018;31(4):351-356. doi:10.1016/j.beha.2018.09.003

BibTeX
@article{Roberts2018,
  author = {Roberts, Kathryn G},
  title = {Why and how to treat Ph-like ALL?},
  journal = {Best Practice & Research Clinical Haematology},
  year = {2018},
  volume = {31},
  number = {4},
  pages = {351--356},
  doi = {10.1016/j.beha.2018.09.003}
}
Kostenlos starten →